Formoterol Turbuhaler® 4.5 μg (delivered dose) has a rapid onset and 12-h duration of bronchodilation

Pulmonary Pharmacology and Therapeutics

Volumn 15, Issue 2, 2002, Pages 175-183

  Selroos, Olof ^a   Ekström, Tommy ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Asthma; Bronchodilation; Formoterol; Turbuhaler; 2 agonist

Indexed keywords

FORMOTEROL; PLACEBO; SALBUTAMOL; TERBUTALINE; BRONCHODILATING AGENT; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; SALMETEROL;

ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FORCED EXPIRATORY VOLUME; HUMAN; META ANALYSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; ADULT; AEROSOL; CHILD; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TIME;

ADULT; AEROSOLS; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOLAMINES; HUMANS; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 0035983359     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.2001.0335     Document Type: Review

References (36)

1. British guidelines on asthma management: 1995 Review and position statement
2. Modern drug treatment of chronic asthma
3. Effect of inhaled formoterol and budesonide on exacerbations of asthma
4. What is new since the last (1999) Canadian Asthma Consensus Guidelines?
5. Rapid onset of action of inhaled formoterol in asthmatic patients
6. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma
7. 2-agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma
8. Onset of bronchodilation and tremor inducing effect of salmeterol and salbutamol (albuterol) up to two hours after inhalation
9. Salmeterol versus formoterol in patients with moderately severe asthma: Onset and duration of action
10. Inhaled formoterol during one year in asthma: A comparison with salbutamol
11. 2-adrenoceptor agonist bronchodilator
12. 2-agonist formoterol
13. Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airway disease
14. Time course of bronchodilating effect of inhaled formoterol, a potent and long-acting sympathomimetic
15. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma
16. Turbuhaler® - A new powder inhaler for administration of drugs to the airways
17. The inhalation device influences lung deposition and bronchodilating effect of terbutaline
18. Importance of the inhalation device on the effect of budesonide
19. 2-agonists in the treatment of asthma?
20. 2-agonist treatment in bronchial asthma
21. 2-agonists
22. Formoterol Turbohaler 6 μg vs. formoterol Aerolizer 12 μg
23. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler®
24. Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI
25. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: Onset of action, duration of effect and potency
26. Formoterol via Turbuhaler® gave better protection than terbutaline against exercise challenge for up to 12 hours in children and adolescents
27. Formoterol in Turbuhaler® is faster and has a more beneficial ratio than salmeterol Diskhaler® in asthmatic children
28. A randomised, double-blind, placebo-controlled, dose response study with formoterol Turbuhaler®
29. A dose-response study with formoterol Turbuhaler® as maintenance therapy in asthmatic patients
30. Low-dose formoterol Turbuhaler® (Oxis®) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.)
31. 2 adrenoceptor agonist: Comparison with salbutamol in adult asthmatic patients
32. Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies
33. A one-week dose-ranging study of inhaled salmeterol in children with asthma
34. Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease